153 related articles for article (PubMed ID: 22616552)
1. ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapy.
Sun JM; Sung JY; Park SH; Kwon GY; Jeong BC; Seo SI; Jeon SS; Lee HM; Jo J; Choi HY; Lim HY
BMC Cancer; 2012 May; 12():187. PubMed ID: 22616552
[TBL] [Abstract][Full Text] [Related]
2. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.
Olaussen KA; Dunant A; Fouret P; Brambilla E; André F; Haddad V; Taranchon E; Filipits M; Pirker R; Popper HH; Stahel R; Sabatier L; Pignon JP; Tursz T; Le Chevalier T; Soria JC;
N Engl J Med; 2006 Sep; 355(10):983-91. PubMed ID: 16957145
[TBL] [Abstract][Full Text] [Related]
3. MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy.
Hoffmann AC; Wild P; Leicht C; Bertz S; Danenberg KD; Danenberg PV; Stöhr R; Stöckle M; Lehmann J; Schuler M; Hartmann A
Neoplasia; 2010 Aug; 12(8):628-36. PubMed ID: 20689757
[TBL] [Abstract][Full Text] [Related]
4. Excision repair cross-complementation group 1 (ERCC1) expression in advanced urothelial carcinoma patients receiving cisplatin-based chemotherapy.
Kim KH; Do IG; Kim HS; Chang MH; Kim HS; Jun HJ; Uhm J; Yi SY; Lim DH; Ji SH; Park MJ; Lee J; Park SH; Kwon GY; Lim HY
APMIS; 2010 Dec; 118(12):941-8. PubMed ID: 21091775
[TBL] [Abstract][Full Text] [Related]
5. ERCC1 as a Prognostic and Predictive Biomarker for Urothelial Carcinoma of the Bladder following Radical Cystectomy.
Klatte T; Seitz C; Rink M; Rouprêt M; Xylinas E; Karakiewicz P; Susani M; Shariat SF
J Urol; 2015 Nov; 194(5):1456-62. PubMed ID: 26162296
[TBL] [Abstract][Full Text] [Related]
6. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy.
Bellmunt J; Paz-Ares L; Cuello M; Cecere FL; Albiol S; Guillem V; Gallardo E; Carles J; Mendez P; de la Cruz JJ; Taron M; Rosell R; Baselga J;
Ann Oncol; 2007 Mar; 18(3):522-8. PubMed ID: 17229776
[TBL] [Abstract][Full Text] [Related]
7. ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy.
Li P; Fang YJ; Li F; Ou QJ; Chen G; Ma G
Br J Cancer; 2013 Apr; 108(6):1238-44. PubMed ID: 23481186
[TBL] [Abstract][Full Text] [Related]
8. The prognostic significance of human equilibrative nucleoside transporter 1 expression in patients with metastatic bladder cancer treated with gemcitabine-cisplatin-based combination chemotherapy.
Matsumura N; Nakamura Y; Kohjimoto Y; Inagaki T; Nanpo Y; Yasuoka H; Ohashi Y; Hara I
BJU Int; 2011 Jul; 108(2 Pt 2):E110-6. PubMed ID: 21166756
[TBL] [Abstract][Full Text] [Related]
9. Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum-based neoadjuvant chemotherapy.
Ozcan MF; Dizdar O; Dincer N; Balcı S; Guler G; Gok B; Pektas G; Seker MM; Aksoy S; Arslan C; Yalcin S; Balbay MD
Urol Oncol; 2013 Nov; 31(8):1709-15. PubMed ID: 22863869
[TBL] [Abstract][Full Text] [Related]
10. Correlation of ERCC1 expression in peripheral blood lymphocytes with outcomes of patients with gastric cancer treated with oxaliplatin-based adjuvant chemotherapy.
Zhang YY; Gu KS; Wu HY; Yang F; Bu LJ; Zhao CC; Zhang YR
Genet Mol Res; 2015 Dec; 14(4):15921-9. PubMed ID: 26662383
[TBL] [Abstract][Full Text] [Related]
11. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
[TBL] [Abstract][Full Text] [Related]
12. ERCC1 expression levels predict the outcome of platinum-based chemotherapies in advanced bladder cancer: a meta-analysis.
Li S; Wu J; Chen Y; Tang W; Peng Q; Deng Y; Xie L; Wang J; Huang S; Li R; Qin X; Zhao J
Anticancer Drugs; 2014 Jan; 25(1):106-14. PubMed ID: 24025563
[TBL] [Abstract][Full Text] [Related]
13. ERCC1 protein, mRNA expression and T19007C polymorphism as prognostic markers in head and neck squamous cell carcinoma patients treated with surgery and adjuvant cisplatin-based chemoradiation.
De Castro G; Pasini FS; Siqueira SA; Ferraz AR; Villar RC; Snitcovsky IM; Federico MH
Oncol Rep; 2011 Mar; 25(3):693-9. PubMed ID: 21206986
[TBL] [Abstract][Full Text] [Related]
14. ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy.
De Dosso S; Zanellato E; Nucifora M; Boldorini R; Sonzogni A; Biffi R; Fazio N; Bucci E; Beretta O; Crippa S; Saletti P; Frattini M
Cancer Chemother Pharmacol; 2013 Jul; 72(1):159-65. PubMed ID: 23645290
[TBL] [Abstract][Full Text] [Related]
15. [Expression and predictive role of excision repair cross complementation group 1, ribonucleotide reductase subunit M1, and β-tubulin 3 in postoperative patients with non-small cell lung cancer receiving adjuvant chemotherapy].
Shi Y; Chen L; Li J; Lü YL; Jiao SC
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2010 Aug; 32(4):375-82. PubMed ID: 20868593
[TBL] [Abstract][Full Text] [Related]
16. Clinical Perspectives of ERCC1 in Bladder Cancer.
Koutsoukos K; Andrikopoulou A; Dedes N; Zagouri F; Bamias A; Dimopoulos MA
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33266377
[TBL] [Abstract][Full Text] [Related]
17. Expression of ERCC1, MSH2 and PARP1 in non-small cell lung cancer and prognostic value in patients treated with platinum-based chemotherapy.
Xie KJ; He HE; Sun AJ; Liu XB; Sun LP; Dong XJ
Asian Pac J Cancer Prev; 2014; 15(6):2591-6. PubMed ID: 24761869
[TBL] [Abstract][Full Text] [Related]
18. ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy.
Hwang IG; Ahn MJ; Park BB; Ahn YC; Han J; Lee S; Kim J; Shim YM; Ahn JS; Park K
Cancer; 2008 Sep; 113(6):1379-86. PubMed ID: 18623378
[TBL] [Abstract][Full Text] [Related]
19. ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer.
Booton R; Ward T; Ashcroft L; Morris J; Heighway J; Thatcher N
J Thorac Oncol; 2007 Oct; 2(10):902-6. PubMed ID: 17909351
[TBL] [Abstract][Full Text] [Related]
20. Differential expression of ERCC1 in pancreas adenocarcinoma: high tumor expression is associated with earlier recurrence and shortened survival after resection.
Maithel SK; Coban I; Kneuertz PJ; Kooby DA; El-Rayes BF; Kauh JS; Sarmiento J; Staley CA; Volkan Adsay N
Ann Surg Oncol; 2011 Sep; 18(9):2699-705. PubMed ID: 21360249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]